tiprankstipranks
Trending News
More News >
Oculis Holding (OCS)
NASDAQ:OCS

Oculis Holding (OCS) AI Stock Analysis

Compare
66 Followers

Top Page

OC

Oculis Holding

(NASDAQ:OCS)

Rating:31Underperform
Price Target:
Oculis Holding's stock performance is primarily hindered by severe financial challenges, with negative margins and declining equity. Technical analysis presents mixed signals, with some short-term upward movement but potential bearish momentum. The valuation is weak due to negative earnings and no dividend yield. Overall, significant improvements are needed in financial performance to enhance stock appeal.
Positive Factors
Clinical Trials
The company reported positive data from the Phase 2 ACUITY trial of privosegtor in acute optic neuritis, indicating positive safety and efficacy.
Market Position
The company's estimated market value has increased to $1.56B, with a raised price target of $32 per share.
Regulatory Progress
Oculis plans to engage with the FDA to align on a registrational path for AON, indicating progress in their developmental pursuits.
Negative Factors
Developmental Challenges
Oculis's ophthalmology portfolio is considered underappreciated relative to peak sales, supporting a Buy rating.
Regulatory Risks
Risks include possible failure of OCS-01 or OCS-02 in clinical trials or to secure regulatory approval, as well as potential dilution risk.

Oculis Holding (OCS) vs. SPDR S&P 500 ETF (SPY)

Oculis Holding Business Overview & Revenue Model

Company DescriptionOculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
How the Company Makes MoneyOculis Holding generates revenue primarily through the development and commercialization of its proprietary ophthalmic therapies. The company's revenue model includes income from the sale of approved drug products, licensing agreements, and strategic partnerships. Oculis collaborates with other pharmaceutical companies to co-develop and market its treatments, often involving upfront payments, milestone payments, and royalties on sales. Additionally, the company may receive funding from research grants and government programs aimed at supporting innovative healthcare solutions.

Oculis Holding Financial Statement Overview

Summary
Oculis Holding faces substantial financial challenges, particularly in profitability and revenue growth, with negative margins across the board. While the company maintains a low debt-to-equity ratio, its equity has been declining. Cash flows are under pressure, with negative free cash flow and limited conversion of losses into operational cash flow. Strategic adjustments are necessary to improve financial health.
Income Statement
20
Very Negative
Oculis Holding's TTM (Trailing-Twelve-Months) income statement shows a gross profit margin of -5747.54% and a net profit margin of -18363.60%, indicating significant operational losses. The revenue growth rate is negative, showing a decrease of 47.11% from the previous year, and both EBIT and EBITDA margins are negative, further emphasizing ongoing financial struggles.
Balance Sheet
30
Negative
The balance sheet reveals a debt-to-equity ratio of 0.02, indicating low leverage, but stockholders' equity has decreased significantly over recent years. The equity ratio is 60.96%, showing a strong equity position relative to total assets, yet the company has faced equity erosion over time.
Cash Flow
25
Negative
Cash flow analysis shows a negative free cash flow growth rate of -11.43%. The operating cash flow to net income ratio is 0.55, reflecting operational inefficiencies. The free cash flow to net income ratio is 0.56, suggesting limited cash flow generation relative to net losses.
Breakdown
TTMDec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
467.00K883.00K912.00K960.00K993.00K
Gross Profit
-26.85M-28.36M-21.31M-8.61M-8.34M
EBIT
-73.20M-80.71M-32.38M-13.23M-12.34M
EBITDA
-86.00M-45.73M-31.95M-12.98M-12.10M
Net Income Common Stockholders
-85.78M-88.80M-38.70M-18.55M-14.87M
Balance SheetCash, Cash Equivalents and Short-Term Investments
46.28M91.65M19.79M46.28M4.95M
Total Assets
58.04M114.35M37.06M58.04M16.38M
Total Debt
114.27M605.00K123.08M114.27M54.81M
Net Debt
68.00M-37.72M103.30M68.00M49.86M
Total Liabilities
119.00M20.63M135.05M119.00M60.04M
Stockholders Equity
-60.95M93.73M-97.99M-60.95M-43.65M
Cash FlowFree Cash Flow
-47.73M-53.89M-28.62M-13.85M-12.05M
Operating Cash Flow
-47.50M-53.84M-25.07M-13.82M-12.03M
Investing Cash Flow
-17.56M-54.21M-3.55M-28.00K-19.00K
Financing Cash Flow
54.03M129.67M1.71M55.19M4.86M

Oculis Holding Technical Analysis

Technical Analysis Sentiment
Positive
Last Price19.92
Price Trends
50DMA
18.07
Positive
100DMA
19.43
Positive
200DMA
17.16
Positive
Market Momentum
MACD
0.43
Negative
RSI
61.10
Neutral
STOCH
60.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OCS, the sentiment is Positive. The current price of 19.92 is above the 20-day moving average (MA) of 18.69, above the 50-day MA of 18.07, and above the 200-day MA of 17.16, indicating a bullish trend. The MACD of 0.43 indicates Negative momentum. The RSI at 61.10 is Neutral, neither overbought nor oversold. The STOCH value of 60.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OCS.

Oculis Holding Risk Analysis

Oculis Holding disclosed 98 risk factors in its most recent earnings report. Oculis Holding reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
The listing of ordinary shares on Nasdaq Iceland Main Market may result in increased additional compliance risk, which could have a material effect on our business, results of operations and financial condition, or may delay or discourage a takeover attempt. Q4, 2024
2.
The dual listing of our ordinary shares may adversely affect the liquidity and value of those ordinary shares. Q4, 2024
3.
The terms of our loan facility place restrictions on our operating and financial flexibility. Q4, 2024

Oculis Holding Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
62
Neutral
$664.19M-40.13%-3.08%
60
Neutral
$567.70M-53.54%12.04%-31.81%
54
Neutral
$5.24B3.27-45.39%2.80%16.77%-0.07%
53
Neutral
$1.02B-56.31%-106.10%
49
Neutral
$1.35B-57.19%-0.33%-3.59%
48
Neutral
$601.53M34.94%
OCOCS
31
Underperform
$1.07B-85.39%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
OCS
Oculis Holding
19.92
7.92
66.00%
EYPT
EyePoint Pharmaceuticals
8.94
-0.14
-1.54%
OCUL
Ocular Therapeutix
9.02
4.04
81.12%
AVXL
Anavex Life Sciences
8.27
4.48
118.21%
MLYS
Mineralys Therapeutics, Inc.
16.12
2.62
19.41%
BCAX
Bicara Therapeutics Inc.
11.50
-13.91
-54.74%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.